Menu
Search
|

Menu

Close
X

Aquinox Pharmaceuticals Inc AQXP.OQ (NASDAQ Stock Exchange Global Market)

2.20 USD
-- (--)
As of Nov 19
chart
Previous Close 2.20
Open --
Volume --
3m Avg Volume 65,125
Today’s High --
Today’s Low --
52 Week High 16.85
52 Week Low 1.98
Shares Outstanding (mil) 23.46
Market Capitalization (mil) 332.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
25
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.137
FY17
-2.238
FY16
-1.963
FY15
-1.795
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
2.67
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-38.16
15.05
Return on Equity (TTM)
vs sector
-38.28
16.62

EXECUTIVE LEADERSHIP

David Main
Co-Founder, President and Chief Executive Officer and Chairman of the Board, Since 2014
Salary: $365,027.00
Bonus: --
Kamran Alam
Chief Financial Officer, Vice President - Finance, Since 2011
Salary: $181,080.00
Bonus: --
Lloyd Mackenzie
Chief Operating Officer, Vice President - R&D Operations, Since 2017
Salary: --
Bonus: --
David Mitchell
Vice President - Global Regulatory Affairs & Quality Assurance, Since 2014
Salary: --
Bonus: --
Barbara Troupin
Chief Medical Officer, Vice President - Clinical Development, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

887 Great Northern Way Suite 450
VANCOUVER   BC   V5T 4T5

Phone: +1604.6299223

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.

SPONSORED STORIES